Reply:
We are very pleased by the interesting comment and participation by Yavaşoğlu. As we already mentioned in the article oral terbinafine is a highly effective agent, which is generally well tolerated. Two large-scale postmarketing surveillance studies showed that the incidence of serious side effects was <1% [1, 2] . We want to clarify that the main purpose of our report was to share the experience of handling such a difficult case with colleagues who are practicing medicine, since the definite causality of aplastic anemia with oral terbinafine cannot be established [3] . The well prepared case presented by Yavaşoğlu and Arslan is another example in this regard [4] . In addition MCV and serum vitamin B12 levels were missing in most of the cases reported in the literature, but they were both in normal ranges in our case.
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Multiple Myeloma and Alkaline Phosphatase
Multipl Myelom ve Alkalen Fosfataz
To the Editor,
The article entitled "Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options", written by Çetin et al. [1] and published in a recent issue of your journal, was quite interesting. Here we would like to emphasize some relevant points.
This study was not homogeneous. It is important that the initial value of total alkaline phosphatase (ALP) be measured. In addition, in that study, had serum intact parathyroid hormone level, vitamin D level, or bone turnover markers been available, they would have provided further biochemical correlates of skeletal metabolism.
Bone-specific ALP may increase in Paget's disease, osteosarcoma, bone metastases of prostatic cancer (high/very high ALP values), other bone metastases, fractured bones, multiple myeloma (only when associated with fractures), osteomalacia, rickets, vitamin D deficiency (moderate rise), malignant tumors (ALP originating from tumors), renal disease (secondary hyperparathyroidism), and primary hypothyroidism [2, 3] .
Vitamin D deficiency is extremely common in multiple myeloma, with 40% of patients having vitamin D levels in the deficient range of levels less than 36 nmol/L, and it represents a surrogate for clinical multiple myeloma disease status [4] .
Vitamin D deficiency can cause osteomalacia and those patients can develop generalized musculoskeletal pain, proximal muscle weakness, and increased risk of falls. This may not be clinically detectable but is nonetheless present and often unrecognized [5] .
